Enlivex doses first patient under amended protocol of Phase II trial

Enlivex Therapeutics announced that the first patient has been dosed under the amended protocol for the Company’s Phase II trial evaluating Allocetra in patients with sepsis. As previously announced, the amended protocol allows a higher SOFA score inclusion range, which allows the recruitment of patients with higher levels of sepsis severity. Additionally, the amended protocol provides for two cohorts rather than the prior protocol’s four-cohort structure.